How are pharmaceutical patent term extensions justified? Australia's evolving scheme

Area of Science:

• Intellectual Property Law
• Pharmaceutical Policy
• Economic Analysis

Background:

• The article analyzes the historical development of patent term extension (PTE) schemes in Australia.
• It traces the legislative changes from the Patents Act 1903 (Cth) to the Patents Act 1990 (Cth).
• The evolution reflects a shift in policy rationale from "inadequate remuneration" to specific pharmaceutical provisions.

Purpose of the Study:

• To critically examine the policy justifications and effectiveness of patent term extension schemes.
• To assess the impact of legislative changes on the objectives and outcomes of PTE.
• To evaluate the current functioning of information provisions within the Patents Act 1990 (Cth) concerning PTE.

Main Methods:

• Historical legal analysis of Australian patent legislation (1903, 1952, 1990 Acts).
• Policy analysis of the rationale behind evolving patent term extension schemes.
• Evaluation of information disclosure requirements and their effectiveness.

Main Results:

• Patent term extension schemes have undergone significant evolution, particularly concerning pharmaceutical patents.
• There are substantial policy questions regarding the overall desirability and justification for patent term extensions.
• Key information provisions in the Patents Act 1990 (Cth) are not functioning effectively to support policy analysis.

Conclusions:

• The justification for patent term extensions requires robust evidence that community benefits outweigh costs.
• Achieving PTE objectives may necessitate restricting competition, raising further policy concerns.
• Improvements to information provisions are needed for a more evidence-based approach to patent term extension policy.